Caris Life Sciences Announces Presentations at ESMO 2017 Highlighting Ability of Its Tumor Molecular Profiling to Develop Therapeutic Strategies

Comprehensive genomic profiling plus of DNA, RNA and proteins enables personalized therapy decisions across immunotherapy, targeted therapy and chemotherapy

News provided by

Caris Life Sciences

Sep 07, 2017, 08:30 ET

IRVING, Texas, Sept. 7, 2017 /PRNewswire/ -- Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced results from two studies that further validate the benefits of its molecular profiling approach in guiding therapeutic strategies in oncology. Each study utilized comprehensive genomic profiling plus (CGP+) with Caris Molecular Intelligence^® to stratify each individual patient's tumor on a molecular level, leading to more therapeutic options and improved outcomes. The data will be presented in two poster presentations at the European Society of Medical Oncology (ESMO) Conference on September 8 – 12, 2017, in Madrid, Spain.

"By identifying the molecular profile of malignant cells, we are enabling the identification of a treatment path that better targets what is causing malignant disease and thus results in better treatment selection and ultimately better patient outcomes," said David Spetzler, M.S., Ph.D., M.B.A., President and Chief Scientific Officer of Caris Life Sciences. "These studies provide further evidence that molecular profiling is a productive approach to assist clinicians in developing a therapeutic path for their patients, particularly in very challenging patients as included in these analyses."

Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune check-point blockade therapy
Poster Display Session
Poster: 100P, Hall 8
September 9, 1:15 – 2:15 p.m. CEDT

Summary: Carcinoma of unknown primary ﴾CUP﴿ tissue accounts for approximately 3% of all malignancies. 389 cases with CUP were evaluated by Next-Generation Sequencing (592 DNA genes and 53 RNA genes) for point mutations, copy number variations, insertions/deletions, fusions, tumor mutational load (TML) and microsatellite instability (MSI), as well as Immunohistochemistry for PD-L1. TML-High was seen in 11.8% and MSI-High in 1.8% of tumors. Sixty-nine different genes were found mutated with incidences ranging from 0.5% to 54%. PDL-1 expression was seen in 22.1% of tumors. Targetable gene fusions were rare (n=3) but they occurred with significantly lower TML and no instances of microsatellite instability. Using a multiplex testing approach, 28% of CUPs had biomarkers of response to the immune check‐point blockade, making CUP one of the most likely indications to benefit from immune checkpoint inhibitors.

Comparison of progression-free survival (PFS) on comprehensive multiplatform profiling-guided therapy to PFS on prior therapy: A pooled analysis from 4 contemporary prospective studies
Poster Display Session
Poster: 1676P, Hall 8
September 11, 1:15 – 2:15 p.m. CEDT

Summary: PFS typically declines with subsequent treatment regimens. However, molecular profiling of tumors to help guide treatment has shown clinical benefit. Data from four independent, physician-led studies included 202 patients whose tissue samples were submitted for comprehensive multiplatform profiling. Clinical benefit was defined as a PFS ratio of ≥1.3 (PFS of profile-driven therapy / PFS of prior therapy). A median PFS of 120 days was observed with CGP+ directed therapies compared to 89.5 days in prior therapies (HR=0.70, p=0.0120). Seventy-three of evaluable 140 patients had a PFS ratio ≥ 1.3. Over 70% of treated patients received chemotherapy alone, while 21% of patients received targeted therapies, either alone or in combination with chemotherapy or hormone therapy. Contrary to the expected decline in PFS, patients had a better outcome when treated with CGP+ guided treatments. This was driven by the precise use of available chemotherapeutic resources rather than expensive and often inaccessible targeted therapies.

About Caris Life Sciences^®Caris Life Sciences^® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. Caris Molecular Intelligence^®, the company's Comprehensive Genomic Profiling Plus (CGP+) molecular testing service and the world's leading immunotherapy diagnostic expert, assesses DNA, RNA and proteins, including microsatellite instability (MSI), total mutational load (TML) and PD-L1, to reveal a molecular blueprint to guide more precise and personalized treatment decisions. The ADAPT Biotargeting System^™, the company's revolutionary and unbiased profiling platform, is currently being utilized for drug target identification, therapeutic discovery and development, fixed tissue-based companion diagnostics, blood-based cancer screening and biomarker identification. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe and other international markets. To learn more, please visit www.CarisLifeSciences.com.

Media Inquiries:
The Ruth Group
Kirsten Thomas / Joanna Zimmerman
Tel: +1-508-280-6592 / +1-646-536-7006
[email protected]

SOURCE Caris Life Sciences